Results about: spin off

IRB Barcelona Innovation’s “triple” boost from the Catalan Government

ACCIÓ awards the Institute’s Innovation Department with the quality seal TECNIO and two VALUNI grants for technology transfer projects

Iproteos closes a round of funding valued at 1.5 million Euros

The biotech will set aside this injection of capital –led by Caixa Capital Risc- to complete the preclinical phase in order to start Human Phase I trials of its compound to the treatment of Cognitive Impairment Associated with Schizophrenia. The drug is one of the few under development worldwide to halt the progression and reverse the symptoms of this condition.

The drug is a first-in-class for the treatment of Cognitive Impairment Associated with Schizophrenia  (CIAS). The compound has been developed using their proprietary IPROTech, a cutting-edge platform the fast and cost-effectively obtaining of innovative drugs.  

Iproteos, settled at the Parc Cientific de Barcelona, is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the technology transfer from IRB Barcelona and the University of Barcelona.

Launch of Nostrum BioDiscovery, a spin-off that applies supercomputing to speed up drug discovery

Nostrum BioDiscovery has come about from the combined efforts of IRB Barcelona and the BSC-CNS—two research centres of excellence in Barcelona—with the participation of the University of Barcelona and ICREA and supported by the Botín Foundation’s technology transfer programme.

The company boasts cutting-edge bioinformatics technologies to speed up the development and lower the cost of designing drugs—which are becoming increasingly more complex and expensive—and to further precision medicine.

”la Caixa” leads an investment round in IRB Barcelona's spin off Inbiomotion

The company concludes a 2.2 million € round led by ”la Caixa” through Caixa Capital Risc. Also participating in the operation were Ysios Capital and Fundación Vila Casas.

Inbiomotion, a spin off founded by IRB Barcelona's group leader, Roger Gomis,  develops diagnostic products for predicting risks that cancer patients may suffer bone metastasis.